The Oncolytic Virus Immunotherapy Market To Continue With Its Monetization At A

Posted by Ashish on May 21st, 2021

The new study report by Persistence Market Research (PMR) reveals that the oncolytic virus immunotherapy market value is all set to reach US$ ~67 Mn, by 2019-end. As per the PMR’s report, the oncolytic virus immunotherapy market is estimated to grow at a CAGR of ~12% over the period of assessment, 2019-2029.

Increasing adoption of adjuvant therapy in developed economies has been fueling the demand for new treatments such as oncolytic virus immunotherapy. For instance, the launch of first FDA approved oncolytic virus, IMLYGIC™ (talimogene laherparepvec) by the leading pharmaceutical manufacturer Amgen has offered oncologists and patients a wider and more targeted treatment approach for overcoming cancer. Amgen’s IMLYGIC™ remains the only FDA approved oncolytic virus immunotherapy drug that is prescribed for melanoma cancer.

Strategizing The Moves For The Next Decade? See Through Sample Of Oncolytic Virus Immunotherapy Market Report! https://www.persistencemarketresearch.co/samples/15262

Company Profiles:

• BioVex, Inc. (Amgen, Inc.)
• Cold Genesys, Inc.
• DNAtrix Therapeutics
• Genelux Corporation
• Lokon Pharma AB
• Oncolytics Biotech, Inc.
• ORYX GmbH & Co. KG
• PsiOxus Therapeutics
• SillaJen, Inc.
• Sorrento Therapeutics, Inc.
• Takara Bio
• Targovax ASA
• Transgene sa
• Turnstone Biologics
• VCN Biosciences